GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » PB Ratio

Acceleron Pharma (Acceleron Pharma) PB Ratio : 15.22 (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Acceleron Pharma's share price is $178.75. Acceleron Pharma's Book Value per Share for the quarter that ended in Sep. 2021 was $11.75. Hence, Acceleron Pharma's PB Ratio of today is 15.22.

The historical rank and industry rank for Acceleron Pharma's PB Ratio or its related term are showing as below:

XLRN' s PB Ratio Range Over the Past 10 Years
Min: 3.46   Med: 6.66   Max: 24.1
Current: 15.22

During the past 10 years, Acceleron Pharma's highest PB Ratio was 24.10. The lowest was 3.46. And the median was 6.66.

XLRN's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs XLRN: 15.22

During the past 12 months, Acceleron Pharma's average Book Value Per Share Growth Rate was -21.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 20.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 26.20% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Acceleron Pharma was 42.50% per year. The lowest was 12.80% per year. And the median was 20.60% per year.

Back to Basics: PB Ratio


Acceleron Pharma PB Ratio Historical Data

The historical data trend for Acceleron Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma PB Ratio Chart

Acceleron Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.33 5.26 6.90 6.27 9.03

Acceleron Pharma Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.55 9.03 10.14 10.00 14.65

Competitive Comparison of Acceleron Pharma's PB Ratio

For the Biotechnology subindustry, Acceleron Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acceleron Pharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acceleron Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Acceleron Pharma's PB Ratio falls into.



Acceleron Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Acceleron Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2021)
=178.75/11.748
=15.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Acceleron Pharma  (NAS:XLRN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Acceleron Pharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acceleron Pharma (Acceleron Pharma) Business Description

Traded in Other Exchanges
N/A
Address
128 Sidney Street, Cambridge, MA, USA, 02139
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Executives
Sujay Kango officer: EVP, Chief Commercial Officer 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin officer: SVP, CFO and Treasurer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness officer: SVP, General Counsel and Sec. C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable director, officer: CEO and President C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co 10 percent owner 430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik director C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139

Acceleron Pharma (Acceleron Pharma) Headlines

From GuruFocus

Acceleron Announces Third Quarter 2021 REBLOZYL� Net Sales

By Business Wire Business Wire 10-27-2021

Acceleron Reports First Quarter 2021 Financial Results

By Business Wire Business Wire 05-06-2021